Efficacy of etrasimod on symptomatic relief in patients with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials

被引：0

作者：

Chaparro, M. ^{[1
]}

Armuzzi, A. ^{[2
]}

Irving, P. M. ^{[3
,4
]}

Allez, M. ^{[5
]}

Dubinsky, M. C. ^{[6
]}

Sands, B. E. ^{[7
]}

Goetsch, M. ^{[8
]}

Wang, W. ^{[9
]}

Shan, K. ^{[10
]}

Woolcott, J. ^{[11
]}

Bartolome, L. ^{[12
]}

Wosik, K. ^{[13
]}

Panaccione, R. ^{[14
]}

机构：

[1] Univ Autonoma Madrid, Hospital Univ Princesa, Inst Invest Sanitaria Princesa IIS Princesa,Gastr, Centro Invest Biomed Red Enfermedades Hepat & Dig, Madrid, Spain

[2] IRCCS Humanitas Res Hosp Rozzano, IBD Ctr, Milan, Italy

[3] Guys & St Thomas NHS Fdn Trust, Gastroenterol, London, England

[4] Kings Coll London, Sch Immunol Microbial Sci, London, England

[5] Univ Paris, Gastroenterol, Hop St Louis, Diderot, France

[6] Icahn Sch Med Mt Sinai, Feinstein IBD Ctr, New York, NY USA

[7] Icahn Sch Med Mt Sinai, Dr Henry Janowitz Div Gastroenterol, New York, NY USA

[8] Pfizer AG, Global Clin Dev, Zurich, Switzerland

[9] Pfizer Inc, Biostat, Collegeville, PA USA

[10] Pfizer Inc, Biostat, New York, NY USA

[11] Pfizer Inc, Global Med Affairs Gastroenterol, Collegeville, PA USA

[12] Pfizer Inc, Global Hlth Econ & Outcomes Res Inflammat &, New York, NY USA

[13] Pfizer Inc, Global Med Affairs Gastroenterol, Kirkland, PQ, Canada

[14] Univ Calgary, Inflammatory Bowel Dis Unit, Div Gastroenterol & Hepatol, Calgary, AB, Canada

来源：

JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

DOP42

引用

页码：I107 / I110

页数：5

共 50 条

[41] Achievement of corticosteroid-free clinical endpoints in subjects with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 trial
Sands, B. E.
Rubin, D. T.
Panes, J.
Gecse, K. B.
Leung, Y.
Goetsch, M.
Wang, W.
Shan, K.
Woolcott, J.
Smith, C. C.
Wosik, K.
Schreiber, S. W.
JOURNAL OF CROHNS & COLITIS, 2023, 17 : I106 - I107
[42] Corticosteroid-Free Efficacy Outcomes in Patients Receiving Concomitant Corticosteroids at Baseline in the Etrasimod ELEVATE UC 52 Trial
Sands, Bruce E.
Leung, Yvette
Rubin, David T.
Gecse, Krisztina B.
Panes, Julian
Goetsch, Martina
Wang, Wenjin
Shan, Kevin
Woolcott, John C.
Smith, Christina C.
Wosik, Karolina
Schreiber, Stefan
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S876 - S877
[43] Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program
Sands, Bruce E.
Dubinsky, Marla C.
Kotze, Paulo G.
Vermeire, Severine
Panaccione, Remo
Long, Millie D.
Woolcott, John C.
Wu, Joseph
Mcdonnell, Aoibhinn
Goetsch, Martina
Bananis, Eustratios
Yarur, Andres J.
INFLAMMATORY BOWEL DISEASES, 2025,
[44] Bowel Urgency and Abdominal Pain in Patients With Moderately to Severely Active Ulcerative Colitis in the Etrasimod ELEVATE UC Clinical Program: A Post Hoc Analysis
Dubinsky, Marla C.
Chaparro, Maria
Armuzzi, Alessandro
Irving, Peter M.
Allez, Matthieu
Panaccione, Remo
Goetsch, Martina
Bartolome, Lauren
Bananis, Eustratios
Wu, Joseph
Wosik, Karolina
Bhattacharjee, Abhishek
Smith, Christina C.
Sands, Bruce E.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S889 - S890
[45] Assessment of age on the efficacy and safety among patients in the etrasimod ELEVATE ulcerative colitis clinical programme
Lichtenstein, G. R.
Allegretti, J. R.
Loftus, E. V., Jr.
Irving, P. M.
Banerjee, R.
Charabaty, A.
Kuehbacher, T.
Bananis, E.
Woolcott, J. C.
Dalam, A. B.
Lazin, K.
Keating, M.
McDonnell, A.
Danese, S.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1320 - I1322
[46] Efficacy and Safety Profile of Etrasimod Was Not Impacted by Baseline Disease Activity: A Post Hoc Analysis of the ELEVATE UC Program
Sands, Bruce E.
Dubinsky, Marla C.
Kotze, Paulo G.
Vermeire, Severine
Panaccione, Remo
Long, Millie D.
Woolcott, John C.
Wu, Joseph
McDonnell, Aoibhinn
Goetsch, Martina
Bananis, Eustratios
Yarur, Andres J.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1044 - S1045
[47] Efficacy and Safety Profile of Etrasimod Was Not Impacted by Baseline Disease Activity: A Post Hoc Analysis of the ELEVATE UC Program
Sands, Bruce E.
Dubinsky, Marla C.
Kotze, Paulo G.
Vermeire, Severine
Panaccione, Remo
Long, Millie D.
Woolcott, John C.
Wu, Joseph
McDonnell, Aoibhinn
Goetsch, Martina
Bananis, Eustratios
Yarur, Andres J.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10): : S1044 - S1045
[48] Etrasimod Corticosteroid-Free Efficacy, Impact of Concomitant Corticosteroids on Efficacy and Safety, and Corticosteroid-Sparing Effect in Ulcerative Colitis: Analyses of the ELEVATE UC Clinical Program
Sands, Bruce E.
Leung, Yvette
Rubin, David T.
Gecse, Krisztina B.
Panes, Julian
Goetsch, Martina
Wang, Wenjin
Woolcott, John C.
Smith, Christina C.
Wosik, Karolina
Schreiber, Stefan
JOURNAL OF CROHNS & COLITIS, 2024,
[49] Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme (APR, jjae038, 2024)
Peyrin-Biroulet, Laurent
Dubinsky, Marla C.
Sands, Bruce E.
Panes, Julian
Schreiber, Stefan
Reinisch, Walter
Feagan, Brian G.
Danese, Silvio
Yarur, Andres J.
D'Haens, Geert R.
Goetsch, Martina
Wosik, Karolina
Keating, Michael
Lazin, Krisztina
Wu, Joseph
Modesto, Irene
McDonnell, Aoibhinn
Bartolome, Lauren
Vermeire, Severine
JOURNAL OF CROHNS & COLITIS, 2024, 18 (08): : 1356 - 1356
[50] Response to etrasimod treatment in ulcerative colitis is associated with a reduction of circulating B and pro-inflammatory T cells: a single-cell-based post-hoc sub-analysis of the ELEVATE UC 52 trial
Weidinger, C.
Milek, M.
Hecker, J.
Haag, L. M.
Freise, I.
Obermayer, B.
Beule, D.
Ryan, R. D.
Crosby, C.
Siegmund, B.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1372 - I1373

← 1 2 3 4 5 →